Back to Crohns Disease And Colitis
NCT01298492
NCT01298492
Who may be able to join
Who might be able to join this trial:
- You must be between 18 and 76 years old.
- You must have already taken part in one of two specific related studies (called A7281006 or A7281008) and completed the first 12 weeks of treatment, and shown signs that the treatment is working (as defined by those studies).
Who may not be able to join:
- You may not be eligible if you finished the 12-week period of the related study but experienced serious side effects linked to the study drug, have an unstable health condition, or if the study doctor feels there is any other reason that would make it unsafe or difficult for you to participate.
- You may not be eligible if you are currently taking azathioprine, 6-mercaptopurine, or methotrexate (medicines often used to suppress the immune system) at any dose.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 2
Sponsor
Shire
Registry
clinicaltrials_gov
Start date
1 July 2011
Est. completion
27 July 2016
Where this trial is recruiting
🇦🇹 Austria
🇧🇪 Belgium
🇨🇦 Canada
🇫🇷 France
🇩🇪 Germany
🇯🇵 Japan
🇳🇱 Netherlands
🇳🇴 Norway
🇵🇱 Poland
🇷🇸 Serbia
🇸🇰 Slovakia
🇿🇦 South Africa
🇰🇷 South Korea
🇪🇸 Spain
🇺🇸 United States
Primary endpoints
Number of Participants With On-Treatment Adverse Events (AEs), AEs Led to Withdrawal, and Serious Adverse Events (SAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.